Truemeds

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Truemeds - overview

Established

2019

Location

Mumbai, Maharashtra, India

Primary Industry

Internet

About

Based in Mumbai, India, and founded in 2019, by founders Akshat Nayyar and Kunal Wani, Intellihealth Solutions Private Limited, aka Truemeds, is a technology-driven, telehealth platform that reduces healthcare expenses and improves healthcare services. The company also offers delivery services for its customers. In March 2025, Intellihealth Solutions Private Limited raised INR 3. 8 billion in series C funding led by new investor Accel, with the participation from returning investors WestBridge Capital Partners and Info Edge (India) Limited.


Truemeds offer teleconsultation, teleradiology, telepathology, and e-pharmacy for chronic illnesses like diabetes, hypertension, and many more. The company also provides an alternative recommendation of medicines that contain the same active ingredients as branded medicines. The company will utilize the March 2025 funding to promote the company and enable its anticipated expansion.


Current Investors

InfoEdge Ventures, Indian Angel Network, Asha Impact

Primary Industry

Internet

Sub Industries

Drug Stores/Convenience Stores, Healthcare IT, Internet

Website

www.truemeds.in

Verticals

E-commerce, HealthTech, Mobile Apps

Company Stage

Series C

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.